Lupin Limited (Lupin), a global pharmaceutical company, has been recognised among India’s Best Employers in the Nation Builders Category 2026 by Great Place To Work® India, securing a place among the Top 14 organisations in the country. The recognition highlights Lupin’s sustained efforts to foster a workplace culture built on trust, inclusion and purpose, while creating a broader impact through expanded access to healthcare, community development initiatives and investments in people. The Nation Builders category honours organisations that demonstrate meaningful contributions beyond business performance by generating employment, developing talent, strengthening communities and supporting the country’s long-term development while maintaining high standards of workplace culture.
Commenting on the achievement, Yashwant Mahadik, President – Global Human Resources, Lupin, said, “This recognition reflects the culture our employees have helped build across the organisation. At Lupin, we remain committed to creating an environment where people are empowered to grow, collaborate and contribute with purpose. By investing in our workforce and nurturing an inclusive workplace, we continue to strengthen our ability to create lasting value for patients, communities and society.”
The organisations featured in the Nation Builders category are selected through an independent evaluation conducted by Great Place To Work® India. The assessment is based on the Trust Index™, which measures employee experience, the Culture Audit™ that evaluates people practices, and additional eligibility parameters that recognise an organisation’s contribution to nation-building.Lupin continues to strengthen its people-centric culture while advancing its mission of improving patient outcomes and expanding access to quality healthcare, reinforcing its commitment to delivering sustainable value for all stakeholders.
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products marketed in more than 100 countries. The company develops and manufactures branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients. It has established a strong presence in India and the United States across key therapeutic areas, including respiratory, cardiovascular, diabetes, anti-infectives, gastrointestinal, central nervous system and women’s health. Lupin operates 15 manufacturing facilities and seven research centres worldwide and employs more than 26,000 professionals
